AU2009303834B2 - Methods and compositions for improving cognitive function - Google Patents

Methods and compositions for improving cognitive function Download PDF

Info

Publication number
AU2009303834B2
AU2009303834B2 AU2009303834A AU2009303834A AU2009303834B2 AU 2009303834 B2 AU2009303834 B2 AU 2009303834B2 AU 2009303834 A AU2009303834 A AU 2009303834A AU 2009303834 A AU2009303834 A AU 2009303834A AU 2009303834 B2 AU2009303834 B2 AU 2009303834B2
Authority
AU
Australia
Prior art keywords
oxo
methyl
hydrogen
alkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2009303834A
Other languages
English (en)
Other versions
AU2009303834A1 (en
Inventor
Michela Gallagher
Rebecca Haberman
Ming Teng Koh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of AU2009303834A1 publication Critical patent/AU2009303834A1/en
Application granted granted Critical
Publication of AU2009303834B2 publication Critical patent/AU2009303834B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2009303834A 2008-10-16 2009-10-16 Methods and compositions for improving cognitive function Active AU2009303834B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US10584708P 2008-10-16 2008-10-16
US61/105,847 2008-10-16
US15263109P 2009-02-13 2009-02-13
US61/152,631 2009-02-13
US17553609P 2009-05-05 2009-05-05
US61/175,536 2009-05-05
PCT/US2009/005647 WO2010044878A1 (en) 2008-10-16 2009-10-16 Methods and compositions for improving cognitive function

Publications (2)

Publication Number Publication Date
AU2009303834A1 AU2009303834A1 (en) 2010-04-22
AU2009303834B2 true AU2009303834B2 (en) 2016-08-11

Family

ID=41403972

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009303834A Active AU2009303834B2 (en) 2008-10-16 2009-10-16 Methods and compositions for improving cognitive function

Country Status (11)

Country Link
US (5) US20100099735A1 (https=)
EP (2) EP2346500B1 (https=)
JP (3) JP5917148B2 (https=)
CN (2) CN102227217A (https=)
AU (1) AU2009303834B2 (https=)
CA (1) CA2740610C (https=)
DK (2) DK3260118T3 (https=)
EA (1) EA033130B1 (https=)
ES (2) ES2865504T3 (https=)
HK (1) HK1245099A1 (https=)
WO (1) WO2010044878A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2865504T3 (es) 2008-10-16 2021-10-15 Univ Johns Hopkins Procedimientos y composiciones para la mejora de la función cognitiva
EP2672822A4 (en) * 2011-02-09 2014-08-27 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTIONS
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
EP2968257A4 (en) * 2013-03-15 2016-08-31 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
JP6433482B2 (ja) 2013-03-15 2018-12-05 エージンバイオ， インコーポレイテッド 認知機能を改善するための方法および組成物
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
MA50634A (fr) * 2015-05-22 2021-04-28 Agenebio Inc Compositions pharmaceutiques à libération prolongée comportant du lévétiracétam
WO2016191288A1 (en) * 2015-05-22 2016-12-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
CN109069480A (zh) 2015-12-30 2018-12-21 阿达玛斯医药公司 用于治疗与癫痫相关的病症的方法和组合物
WO2017198862A1 (en) * 2016-05-20 2017-11-23 Institut Pasteur Methods of treating sepsis with synaptic vesicle 2a and/or 2b binding chemical entities
US10370561B2 (en) 2016-06-28 2019-08-06 Prc-Desoto International, Inc. Urethane/urea-containing bis(alkenyl) ethers, prepolymers prepared using urethane/urea-containing bis(alkenyl) ethers, and uses thereof
US11098222B2 (en) 2018-07-03 2021-08-24 Prc-Desoto International, Inc. Sprayable polythioether coatings and sealants
CN109892247B (zh) * 2019-04-19 2023-08-18 桂林医学院 一种猫参与的检测大鼠认知功能的实验装置
CN112569216B (zh) * 2019-09-30 2022-02-15 厦门大学 戊酸衍生物在治疗唐氏综合征中的应用
CN116075302A (zh) * 2020-07-10 2023-05-05 艾吉因生物股份有限公司 GABAAα5激动剂和SV2A抑制剂的组合以及在认知损害的治疗中的使用方法
JP2024508052A (ja) * 2021-02-26 2024-02-21 シンデシ セラピューティクス ソシエテ アノニム 認知障害の治療のための化合物
CN120584115A (zh) 2022-08-19 2025-09-02 艾吉因生物股份有限公司 苯并氮杂䓬衍生物、组合物和用于治疗认知损害的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070135514A1 (en) * 2002-12-03 2007-06-14 Berkley Lynch Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1309692A (en) 1970-02-13 1973-03-14 Ucb Sa N-substituted lactams
GB1039113A (en) 1964-08-06 1966-08-17 Ucb Sa New n-substituted lactams
IT1045043B (it) * 1975-08-13 1980-04-21 Isf Spa Derivati pirrolidinici
IT1075280B (it) * 1977-02-11 1985-04-22 Isf Spa Procedimento per la preparazione di derivati pirrolidinici
BE864269A (fr) * 1977-03-03 1978-06-16 Parke Davis & Co Nouveaux n-(aminoalkyl substitue)-2-oxo-1-pyrrolidine-acetamides et procedes pour les produire
EP0005689B1 (fr) * 1978-05-08 1981-03-18 U C B, S.A. Nouveaux acides lactame-N-acétiques et leurs amides, leurs procédés de préparation et compositions thérapeutiques
US4654370A (en) 1979-03-12 1987-03-31 Abbott Laboratories Glyceryl valproates
US4372960A (en) * 1980-12-12 1983-02-08 Warner-Lambert Company Quaternary derivatives of N-(substituted-aminoalkyl)-2-oxo-1-pyrrolidine-acetamides as cognition activators
FR2515179A1 (fr) * 1981-07-24 1983-04-29 Hoffmann La Roche Derives de pyrrolidine, leur procede de preparation, les intermediaires pour leur synthese et leur application therapeutique
IL67623A (en) * 1983-01-05 1984-09-30 Teva Pharma 1'-ethoxycarbonyloxyethyl ester of valproic acid,its preparation and pharmaceutical compositions containing it
IL72381A (en) 1983-07-20 1988-03-31 Sanofi Sa Pharmaceutical composition based on valproic acid
US4558070A (en) 1983-10-26 1985-12-10 Abbott Laboratories Acid salts of valproic acid
GB8412358D0 (en) * 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
GB8412357D0 (en) * 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
US4668687A (en) * 1984-07-23 1987-05-26 Bristol-Myers Company Psychogeriatric 1-(2-pyrimidinyl)piperazinyl derivatives of 1-pyrrolidin-2-ones
US4913906B1 (en) 1985-02-28 2000-06-06 Yissum Res Dev Co Controlled release dosage form of valproic acid
JPS6222785A (ja) * 1985-07-23 1987-01-30 Sanwa Kagaku Kenkyusho:Kk 新規な２−オキソピロリジン化合物及びその塩、その製法並びにこれらを有効成分とする脳機能障害の予防及び治療剤
IT1190133B (it) * 1986-06-19 1988-02-10 Chiesi Farma Spa Derivati di acido valproico e di acido (e)-2-valproenoico,procedimento per la loro preparazione e relative composizioni farmaceutiche
DE3709230A1 (de) * 1987-03-20 1988-10-06 Desitin Arzneimittel Gmbh Neues calciumsalz der valproinsaeure
JPS6422883A (en) * 1987-07-17 1989-01-25 Sanwa Kagaku Kenkyusho Co 1-pyrrolidine acetamide derivative, its salt, production thereof and prophylactic and remedial agent for cereral dysfunction containing said derivative and salt as active ingredient
ATE68346T1 (de) 1987-07-22 1991-11-15 Farvalsa Ag Feuchtigkeitsstabile feste valproinsaeurezubereitung und verfahren zu ihrer herstellung.
CA2007732A1 (en) 1989-01-17 1990-07-17 Gary L. Olson Cyclohexaneacetamide derivatives
FR2643556B1 (fr) 1989-02-27 1993-03-05 Sanofi Sa Composition pharmaceutique a liberation prolongee d'acide valproique
IT1231477B (it) * 1989-07-12 1991-12-07 Sigma Tau Ind Farmaceuti (pirrolidin-2-one-1-il) acetammidi quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti
SK279285B6 (sk) * 1991-05-02 1998-09-09 Daiichi Pharmaceutical Co. Použitie n-(2,6-dimetylfenyl)-2-(2-oxo-1-pyrolidin
US5439930A (en) * 1992-04-14 1995-08-08 Russian-American Institute For New Drug Development Biologically active n-acylprolydipeptides having antiamnestic, antihypoxic and anorexigenic effects
US5440023A (en) * 1992-09-18 1995-08-08 Beckman Instruments, Inc. Method for making valproic acid derivatives
GB9319732D0 (en) * 1993-09-24 1993-11-10 Ucb Sa Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety
US5468733A (en) 1993-09-30 1995-11-21 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5516759A (en) 1994-12-08 1996-05-14 Tap Holdings Inc. LHRH antagonists having lactam groups at the N-terminus
IT1285801B1 (it) 1996-10-10 1998-06-24 Sigma Tau Ind Farmaceuti Procedimento migliorato per la preparazione dell'acido valproico
US6131106A (en) * 1998-01-30 2000-10-10 Sun Microsystems Inc System and method for floating-point computation for numbers in delimited floating point representation
US6620802B1 (en) * 1999-11-23 2003-09-16 Corcept Therapeutics, Inc. Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist
AR026610A1 (es) 1999-12-01 2003-02-19 Ucb Sa Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
EP1356812B1 (en) * 2000-12-28 2009-05-13 Hamilton Pharmaceuticals, Inc. Medicines for treatment and prevention of neurogenic pain
US6610326B2 (en) * 2001-02-16 2003-08-26 Andrx Corporation Divalproex sodium tablets
US20040116505A1 (en) * 2001-02-23 2004-06-17 Gregory Krauss Treatment of tics, tremors and related disorders
WO2002094787A1 (en) 2001-05-23 2002-11-28 Ucb, S.A. 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders
JP2005501108A (ja) * 2001-08-22 2005-01-13 第一製薬株式会社 神経変性治療におけるネフィラセタムの使用
IL161317A0 (en) 2001-10-16 2004-09-27 Memory Pharm Corp 4-(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidone derivatives as pde-4 inhibitors for the treatment of neurological syndromes
US20040116506A1 (en) * 2002-06-20 2004-06-17 Krusz John Claude Use of levetiracetam for treating or preventing acute headaches
US7557137B2 (en) * 2002-08-05 2009-07-07 Bristol-Myers Squibb Company Gamma-lactams as beta-secretase inhibitors
US7090985B2 (en) * 2002-12-03 2006-08-15 Ucb, S.A. Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
ITMI20030573A1 (it) * 2003-03-24 2004-09-25 Nikem Research Srl Composti ad azione nootropica, loro preparazione,
TW200508197A (en) 2003-03-31 2005-03-01 Ucb Sa Indolone-acetamide derivatives, processes for preparing them and their uses
EA010031B1 (ru) 2003-12-02 2008-06-30 Юсб, С.А. Производные имидазола, способы их получения и применения
US7618978B2 (en) 2004-04-22 2009-11-17 Eli Lilly And Company Amides as BACE inhibitors
BRPI0511956A (pt) 2004-06-11 2008-01-22 Ucb Sa processo para a preparação dos compostos, e, intermediários de sìntese
US20060063707A1 (en) * 2004-09-17 2006-03-23 Lifelike Biomatic, Inc. Compositions for enhancing memory and methods therefor
CN101111245A (zh) * 2005-01-27 2008-01-23 阿雷姆贝克有限公司 左乙拉西坦延长释放制剂
US20070298098A1 (en) * 2005-02-16 2007-12-27 Elan Pharma International Limited Controlled Release Compositions Comprising Levetiracetam
WO2006102750A1 (en) * 2005-03-30 2006-10-05 Genpharm Inc. Combined-step process for pharmaceutical compositions
US8178533B2 (en) 2005-06-01 2012-05-15 Ucb Pharma, S.A. 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
EP1731149A1 (en) * 2005-06-08 2006-12-13 Ucb S.A. Use of 2-oxo-1-pyrrolidone derivatives for the treatment of diseases characterized by progressive myoclonic epilepsy
GB0517740D0 (en) 2005-08-31 2005-10-12 Novartis Ag Organic compounds
EP1963325A2 (en) 2005-12-07 2008-09-03 UCB Pharma, S.A. Xanthine derivatives, processes for preparing them and their uses
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20070244143A1 (en) * 2006-03-08 2007-10-18 Braincells, Inc Modulation of neurogenesis by nootropic agents
JP2009536667A (ja) * 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド ５ｈｔ受容体介在性の神経新生
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
US20080014264A1 (en) * 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
EP2051696A2 (en) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
AU2007346591A1 (en) 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of ADHD
US20100222326A1 (en) 2007-04-27 2010-09-02 Ucb Pharma, S.A. New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders
KR20090031333A (ko) 2007-09-21 2009-03-25 주식회사 엘지생명과학 신규한 베타-세크리타제 저해용 화합물
US20090176740A1 (en) 2007-11-30 2009-07-09 Phillips Ii Dauglas James Treatment of neurological conditions by the co-administration of aniracetam and l-alpha glycerylphosphorylcholine
PL2273975T3 (pl) * 2008-03-03 2014-09-30 Ucb Pharma Sa Roztwory farmaceutyczne, sposoby wytwarzania i zastosowania terapeutyczne
JP2010024156A (ja) 2008-07-16 2010-02-04 Ucb Pharma Sa レベチラセタムを含む医薬組成物
MX2011001384A (es) 2008-08-06 2011-09-27 Gosforth Ct Holdings Pty Ltd Composiciones y metodos para tratar trastornos psiquiatricos.
ES2865504T3 (es) 2008-10-16 2021-10-15 Univ Johns Hopkins Procedimientos y composiciones para la mejora de la función cognitiva
US9125898B2 (en) * 2008-11-14 2015-09-08 Neurotune Ag Acetam derivatives for pain relief
EP2358360B1 (en) 2008-11-18 2016-09-14 UCB Biopharma SPRL Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivative
CN104906085A (zh) 2009-01-29 2015-09-16 Ucb医药有限公司 含有2-氧代-1-吡咯烷衍生物的药物组合物
WO2010089372A1 (en) 2009-02-09 2010-08-12 Ucb Pharma, S.A. Pharmaceutical compositions comprising brivaracetam
EP2461808A2 (en) 2009-08-07 2012-06-13 UCB Pharma S.A. Methods for enhancing the cognitive function
WO2016191288A1 (en) * 2015-05-22 2016-12-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070135514A1 (en) * 2002-12-03 2007-06-14 Berkley Lynch Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases

Also Published As

Publication number Publication date
DK3260118T3 (da) 2021-04-19
CA2740610C (en) 2020-01-07
EA201170571A1 (ru) 2011-12-30
JP6271641B2 (ja) 2018-01-31
US20100099735A1 (en) 2010-04-22
BRPI0920342A2 (pt) 2020-06-23
DK2346500T3 (en) 2017-07-17
JP2014169339A (ja) 2014-09-18
EA033130B1 (ru) 2019-08-30
HK1245099A1 (zh) 2018-08-24
AU2009303834A1 (en) 2010-04-22
EP2346500A1 (en) 2011-07-27
US20220218665A1 (en) 2022-07-14
CN102227217A (zh) 2011-10-26
CN107243007A (zh) 2017-10-13
EP2346500B1 (en) 2017-05-17
HK1248543A1 (en) 2018-10-19
JP2012505883A (ja) 2012-03-08
JP5917148B2 (ja) 2016-05-11
US20240293363A1 (en) 2024-09-05
EP3260118B1 (en) 2021-03-24
US20150094352A1 (en) 2015-04-02
ES2637497T3 (es) 2017-10-13
JP2016147915A (ja) 2016-08-18
WO2010044878A1 (en) 2010-04-22
EP3260118A1 (en) 2017-12-27
CA2740610A1 (en) 2010-04-22
US20120046336A1 (en) 2012-02-23
ES2865504T3 (es) 2021-10-15
US8604075B2 (en) 2013-12-10

Similar Documents

Publication Publication Date Title
US20240293363A1 (en) Methods and compositions for improving cognitive function
US20230277501A1 (en) Methods and compositions for improving cognitive function
US20230033195A1 (en) Methods and compositions for improving cognitive function
US20160030391A1 (en) Methods and compositions for improving cognitive function
HK1248543B (en) Methods and compositions for improving cognitive function
HK1160007A (en) Methods and compositions for improving cognitive function
HK1160007B (en) Methods and compositions for improving cognitive function
EA044839B1 (ru) Способы и композиции для улучшения когнитивной функции
BRPI0920342B1 (pt) Uso de levetiracetam e de brivracetam, bem como de seus derivados ou análogos ou sais farmaceuticamente aceitáveis dos mesmos
HK1160005A (en) Methods and compositions for improving cognitive function
RU2792010C2 (ru) Способы и композиции для улучшения когнитивных функций
HK1261244A1 (en) Levetiracetam for improving cognitive function

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)